Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin

Oncogene

Volumn 36, Issue 2, 2017, Pages 254-262

  Elf, S ^a   Lin, R ^a   Xia, S ^a   Pan, Y ^a   Shan, C ^a   Wu, S ^a   Lonial, S ^a   Gaddh, M ^a   Arellano, M L ^a   Khoury, H J ^a   Khuri, F R ^a   Lee, B H ^b   Boggon, T J ^c   Fan, J ^a   Chen, J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; DIHYDROARTEMISININ; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; PHOSPHOGLUCONATE DEHYDROGENASE; PHYSCION; REACTIVE OXYGEN METABOLITE; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; EMODIN;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CHRONIC MYELOID LEUKEMIA; CLINICAL OBSERVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; K-562 CELL LINE; LEUKEMIA; LEUKEMIA CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIMALARIALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARTEMISININS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; EMODIN; FEMALE; HUMANS; K562 CELLS; LEUKEMIA; MICE; MICE, NUDE; PENTOSE PHOSPHATE PATHWAY; PHOSPHOGLUCONATE DEHYDROGENASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84976307800     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.196     Document Type: Article

References (15)

1. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009; 461: 109-113
2. Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, et al. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol 2015; 17: 1484-1496
3. Beutler E. G6PD deficiency. Blood 1994; 84: 3613-3636
4. Vives Corrons JL, Colomer D, Pujades A, Rovira A, Aymerich M, Merino A, et al. Congenital 6-phosphogluconate dehydrogenase (6PGD) deficiency associated with chronic hemolytic anemia in a Spanish family. Am J Hematol 1996; 53: 221-227
5. Caprari P, Caforio MP, Cianciulli P, Maffi D, Pasquino MT, Tarzia A, et al. 6-Phosphogluconate dehydrogenase deficiency in an Italian family. Ann Hematol 2001; 80: 41-44
6. Wang SJ, Sun B, Cheng ZX, Zhou HX, Gao Y, Kong R, et al. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-kappaB pathway. Cancer Chemother Pharmacol 2011; 68: 1421-1430
7. Di JM, Pang J, Sun QP, Zhang Y, Fang YQ, Liu XP, et al. Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells. Mol Biol Rep 2010; 37: 1849-1855
8. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 2010; 1804: 581-591
9. Hadad S, Appleyard V, Murray K, Baker L, Huang X, Alessi DR, et al. A-769662 is an AMP kinase-dependant growth inhibitor in brEast cancer cell lines. 2008 ASCO BrEast Cancer Symposium 2008; Abstract No: 170
10. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase and induces autophagy in colorectal cancer cells. Gastroenterology 2012; 142: 1504-1515.e3
11. Spears LD, Qin C, Zhang Z, Ralston L, Fisher JS. The ATM activator chloroquine stimulates phosphorylation of AMP activated protein kinase (AMPK) and acetyl CoA-carboxylase (ACC) independent of ATM. FASEB J 2010; 24 (Meeting Abstract Supplement): lb674
12. Ha J, Daniel S, Broyles SS, Kim KH. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem. 1994; 269: 22162-22168
13. Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on brEast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 2014; 16: 746-752
14. Choudhury Y, Yang Z, Ahmad I, Nixon C, Salt IP, Leung HY. AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience 2014; 1: 446-456
15. Chakrabarti KR, Whipple RA, Boggs AE, Hessler LK, Bhandary L, Vitolo MI, et al. Pharmacologic regulation of AMPK in brEast cancer affects cytoskeletal properties involved with microtentacle formation and re-attachment. Oncotarget 2015; 6: 36292-36307